Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrotinib + thalidomide
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy of pyrotinib and thalidomide being investigated for the treatment of advanced non-small-cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) exon 20 insertions. Pyrotinib is an irreversible EGFR/HER2 dual tyrosine kinase inhibitor, while thalidomide is an antiangiogenic and immunomodulatory drug that functions as a cereblon-based molecular glue. The addition of thalidomide to pyrotinib is expected to both increase clinical benefit and reduce the incidence of pyrotinib-related diarrhea.
- Brand names
- AiRuiNiThalomid
- Other names
- Pyrotinib combined with thalidomidePyrotinib + Thalidomide
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)CRBN (Cereblon)IKZF3 (Zinc finger protein Aiolos)IKZF1 (Ikaros family zinc finger protein 1)
Beyond the preview
Go deeper on pyrotinib + thalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrotinib + thalidomide.